Biotherapy of cancer by targeting TP-3/P80

Details Biotherapy of cancer by targeting TP-3/P80 Biotherapy of cancer by targeting TP-3/P80

1995-01-13

1997-11-25

Feisee, Lila

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated to proteinaceous toxin or fragment thereof

4241431, 4241551, 514 2, 530866, 5303917, 5303877, 53038822, 530370, A61K 3944, C07K 14415, C07K 1628, C12N 1513

Patent

active

056909357

ABSTRACT:
Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.

REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4350626 (1982-09-01), Masuho et al.
patent: 4357273 (1982-11-01), Masuho et al.
patent: 4359457 (1982-11-01), Neville, Jr. et al.
patent: 4363758 (1982-12-01), Masuho et al.
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4379145 (1983-04-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4450154 (1984-05-01), Masuho et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4792447 (1988-12-01), Uhr et al.
patent: 4806494 (1989-02-01), Pastan et al.
patent: 4831117 (1989-05-01), Uckun
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4906469 (1990-03-01), Jansen et al.
patent: 4916213 (1990-04-01), Scannon et al.
patent: 4956453 (1990-09-01), Bjorn et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 5167956 (1992-12-01), Neville, Jr. et al.
Bolognesi et al. Clin. Exp. Immunol., 89:341 (1992).
Bruland, et al. Cancer Research, 48:5302(1988).
Bruland et al. Int. J. Cancer. 38:27 (1986).
Canevari et al. Annals. of Oncology, 5, 698-701 (1994).
Cheung et al. J. Nat. Cancer Instit., 77, 739 (1985).
Chin et al. Hybridoma, 5, 339 (1986).
Dore et al. Nucl. Acids Res., 21:4200-4205 (1993).
Embleton, et al. Cancer Res., 46:5524-28(Nov. 1986).
Fodstad, et al. Int. J. Cancer, 38:33(1986).
Ghettie et al. Blood, 84:702-707 (Aug. 1994).
Gottstein et al. Annals of Oncology, 5, S97 (1994).
Gunther et al. Leukemia, 7:298-309(Feb. 1993).
Hertler et al. J. Clin. Oncol., 7, 1932 (1989).
Hosi, et al. Cancer Research, 42:654(1982).
Houston, et al. Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, pp. 71-96(1987).
Irvin et al. Pharmacology and Therapeutics, 55:279(1992).
Jansen et al. Leukemia, 7:290(1992).
Kersey et al. Third International Symposium on Immunotoxins, Jun. 19-21, 1992, Orlando, FL, p. 95.
Mendelsohn J. Nat'l Cancer Inst., 13:125-131 (1992).
Myers et al. PNAS USA, 92:9575-9579(1995).
Myers et al. Transplantation, 46:240(1988).
Myers, et al. J. Immun. Methods, 136:221-238(1991).
Naramura Cancer Immunol. Immunother., 37:343-349 (1993).
Pastan et al. Cell, 47, 641 (1986).
Perentesis et al. Biofactors, 3:178-184 (1992).
Perentesis et al. PNAS USA, 85, 8386 (1988).
Ramsay et al. 3rd Int'l. Symposium on Immunotoxins, Jun. 1992, Orlando FL.
Rivera et al. The New England J. of Med., 329:1289-1295(Oct. 28, 1993).
Thomas Drugs of Today, 28:311-331 (1992).
Tsai, et al. Cancer Research, 50:152(1990).
Tsang, et al. J. Nat. Cancer Inst., 77:1175(1986).
Uckun Antibody Immunoconjugates and Radiopharmaceutics, 1:247 (1988).
Uckun et al. Blood, 71:13 (1988).
Uckun Brit. J. Haematol., 85:435 (Nov. 9, 1993).
Uckun et al. Blood, 79:2649-2661(May 1992).
Uckun et al. Blood, 79:2201(May 1, 1992).
Uckun et al. Blood, 76:2449(1990).
Uckun et al. In:Human Tumor Antigens and Specific Tumor Therapy, pp. 231-241, R. Metzger & M. Mitchell eds 1989 Alan R Liss, Inc NY, NY.
Uckun et al. J. Exp. Med., 163:347(1986).
Uckun et al. Third International Symposium on Immunotoxins, Jun. 19-21, 1992, Orlando, FL, p. 131.
Uckun, et al. Int. J. Radiat. Biol., 56:611-615(1989).
Uckun, et al. J. Immunol., 134:2010(1985).
Uckun, et al. Leukemia, 7:341(Feb. 1993).
Vitetta et al. In:Biologic Therapy of Cancer, pp. 428-495 (1991), Devita et al eds., J.P. Lippincott Co.
Vitetta et al. Science, 225:1098-1104(1987).
Wada et al. Cancer Research 48:2273 (1988).
Wingo et al. A Cancer J. for Clinicians, 45:8-30 (Jan./Feb. 1995).
Bruland et al Br. J. Cancer 56(1):21-25 (1987).
Erice et al Antimicrob. Agents Chemotherap. 37(4):835-838 (1993).
Anderson et al Cancer Res 55:1321-1327 (1995).
Anderson, Peter M.et al: Cancer Research,(1995), 55(6), 1321-7 CODEN: CNREA8;ISSN: 0008-5472, 1995, XP002002853.
Roth, J.A. et al: Database Embase, Elsevier Science Publishers, Abstract & Cancer, vol. 41, No. 3, 1978, pp. 814-819.
P.M. Anderson et al: (TP-3-PAP), Anticancer Research & Abstracts of the Fifth Internat.Conference of Anticancer Research, Sep. 1995-Oct. 1995, vol. 15, No. 5A.
Gellego J. et al.: Database Embase vol. 21, No. 11, 1985, pp. 511-521.
Frank M. Balis et al., "General Principles of Chemotherapy," Principles of Multimodal Therapy, Chapter 10, 197-245.
O.S. Bruland et al., "Immunoscintigraphy and Radioimmunotherapy: Useful Approaches in the Management of Osteogenic Sarcoma?," Frontiers of Osteosarcoma Research, Novak et al., eds., Hogrefe and Huber, 149-159 (1993).
A.D. Elias et al., "Adjuvant Chemotherapy for Soft Tissue Sarcoma: An Approach in Search of an Effective Regimen," Seminars in Oncology, 16, 305-311 (Aug. 1989).
M.J. Folkman, "Antiangiogenesis," Alternative Strategies for Biologic Therapy, Chapter 30, 743-753. (1991).
E. Frei III et al., "Osteogeneic Sarcoma: The Development of Curative Treatment," Frontiers of Osteosarcoma Research, Novak et al., eds., Hogrefe and Huber, 5-13 (1991).
E.F. McClay, "Epidemiology of Bone and Soft Tissue Sarcomas," Seminars in Oncology, 16, 264-272 (Aug. 1989).
E.F. McClay et al., "Immunotherapeutic Approaches to the Treatment of Bone and Soft Tissue Sarcomas," Seminars in Oncology, 16, 328-332 (Aug. 1989).
P.A. Meyers et al., "Osteogenic Sarcoma with Clinically Detectable Metastasis at Initial Presentation," J. of Clin. Oncology, 11, 449-453 (Mar. 1993).
A.K. Raymond et al., "Osteosarcoma Chemotherapy Effect: A Prognostic Factor," Seminars in Diagnostic Pathology, 4, 212-236 (Aug. 1987).
W.G. Ward et al., "Pulmonary Metastases of Stage IIB Extremity Osteosarcoma and Subsequent Pulmonary Metastases," J. of Clin. Oncology, 12, 1849-1858 (Sep. 1994).
K. Winkler et al., "Neoadjuvant Chemotherapy of Osteosarcoma: Results of a Randomized Cooperative Trail (COSS-82) with Salvage Chemotherapy Based on Histological Tumor Response," J. of Clin. Oncology, 6, 329-337 (Feb. 1988).
American Cancer Society: Cancer Facts & Figures--1994, Publication 94-375M-No. 5008.94, New York, American Cancer Society, Inc., pp. 1-28 (1994).
Byers, V.S. et al. Cancer Research 47:5042-5046, Oct. 1987.
Haines, D.M. and Bruland, O.S. Anticancer Research 9:903-908, 1989.
Ramakrishnan, S. and Huston, L.L. Cancer Research 44(4):1398-1404, Apr. 1984.

Affiliated with

Also associated with

Rating

Biotherapy of cancer by targeting TP-3/P80 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biotherapy of cancer by targeting TP-3/P80, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotherapy of cancer by targeting TP-3/P80 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2104450